Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3797189 | 1.00 | CA2 (0.38) | CA2 | |
| SCHEMBL4732017 | 1.00 | CA2 (0.38) | CA2 | |
| SCHEMBL1533866 | 0.92 | — | — | |
| SCHEMBL10308667 | 0.90 | CA2 (0.35) | CA2 | |
| SCHEMBL27637766 | 0.82 | — | — | |
| Cesium SCHEMBL8429146 | 0.80 | CA2 (0.42) | CA2 | |
| SCHEMBL178840 | 0.79 | ALDH1A1 (0.31) | — | |
| SCHEMBL19619507 | 0.79 | CA2 (0.33) | CA2 | |
| SCHEMBL20034383 | 0.79 | ALDH1A1 (0.41) | — | |
| SCHEMBL3799045 | 0.79 | CYP3A4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150030541-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2015-01-29 | — | — | US | disclosed |
| US-20150030541-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2015-01-29 | — | — | US | disclosed |
| US-20150030541-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2015-01-29 | — | — | US | disclosed |
| US-8889657-B2 | Nanoparticle PEG modification with H-phosphonates | MALLINCKRODT LLC (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889657-B2 | Nanoparticle PEG modification with H-phosphonates | MALLINCKRODT LLC (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130066086-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | MALLINCKRODT LLC (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130066086-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | MALLINCKRODT LLC (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150030541-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | PHOSPHO1, PHPT1, HPSE | CA2 3862/4885 |
| US-20130066086-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | PHOSPHO1, PHPT1, HPSE | CA2 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.